Geopolitics Prime

@geopolitics_prime Β· news Β· English Β· active

Subscribers 289K Subscribers, last 30 days: 289K β†’ 289K +0 24h
Reach per post (ERR) 4.4%12.8K avg views
Posting 36.3/day last 29 minutes ago
Reactions per 1K views 16.6 πŸ’© ❀ 🀬

πŸ’Š Big pharma giant Pfizer doubles down on failed cancer drug The US pharmaceutical behemoth is looking for a way to salvage its experimental drug Sigvotatug Vedotin - even though a key clinical trial failed to demonstrate survival benefits in patients with advanced, inoperable lung cancer, reports Bloomberg. Pfizer acquired the drug through its $43 billion purchase of Seagen, betting on a new class of treatments designed to deliver potent cancer-killing compounds directly to tumors. Now, the drugmaker is looking for ways to make that investment pay off. πŸ‘‰ Patients who received less chemotherapy before taking the drug lived over two months longer than others - possibly due to stronger immune systems, Jeff Legos, Pfizer’s chief oncology officer, argued at a European Society for Medical Oncology conference. The company is now testing its drug alongside Merck's cancer drug Keytruda in a Phase 3 trial involving patients with non-small cell lung cancer, hoping that combination will prove more effective. πŸ‘ Substack | Chat | @geopolitics_prime

Views over time

05K10K15K25 Oct 12:4710 Nov 14:4813.3K25 Oct 12:47: 0 views10 Nov 14:48: 13,300 views
Snapshots we took after posting.
WhenViews
25 Oct 2026, 12:470
10 Nov 2026, 14:4813.3K

Who shared this post

Posts in other channels we index that link to this one. (Forwards with a hidden source can't be traced.)

Nobody yet.